CLINICAL STUDY

OPEN ACCESS Check for updates

Taylor & Francis

Taylor & Francis Group

Development and deployment of interpretable machine-learning model for predicting in-hospital mortality in elderly patients with acute kidney disease

Mingxia Li^a (b), Qinghe Zhuang^b, Shuangping Zhao^{a,c,d}, Li Huang^a, Chenghuan Hu^a, Buyao Zhang^a and Qinlan Hou^a

^aDepartment of Critical Care Medicine, Xiangya Hospital Central South University, Changsha, China; ^bSchool of Computer Science and Engineering, Central South University, Changsha, China; ^cNational Clinical Research Center for Geriatric Disorders, Changsha, China; ^dHunan Provincial Clinical Research Center of Intensive Care Medicine, Changsha, China

ABSTRACT

Background: Acute kidney injury (AKI) is more likely to develop in the elderly admitted to the intensive care unit (ICU). Acute kidney disease (AKD) affects \sim 45% of patients with AKI and increases short-term mortality. However, there are no studies on the prognosis of AKD in the elderly.

Methods: Data from 2666 elderly patients with AKD in the Medical Information Mart for Intensive Care IV were used for model development and 535 in the elCU Collaborative Research Database for external validation. Based on 5 machine learning algorithms, 33 noninvasive parameters were extracted as features for modeling.

Results: In-hospital mortality of AKD in the elderly was 29.6% and 31.8% in development and validation cohorts, respectively. The comprehensive best-performing algorithm was the support vector machine (SVM), and a simplified online application included only 10 features employing SVM (AUC: 0.810 and 0.776 in the training and external validation cohorts, respectively) was deployed. Model interpretation by SHapley Additive exPlanation (SHAP) values revealed that the difference (AKD day – ICU day) in sequential organ failure assessment (delta SOFA), Glasgow coma scale (GCS), delta GCS, delta peripheral oxygen saturation (SpO2), and SOFA were the top five features associated with prognosis. The optimal target was determined by SHAP values from partial dependence plots.

Conclusions: A web-based tool was externally validated and deployed to predict the early prognosis of AKD in the elderly based on readily available noninvasive parameters, assisting clinicians in intervening with precision and purpose to save lives to the greatest extent.

ARTICLE HISTORY

Received 23 August 2022 Revised 12 October 2022 Accepted 24 October 2022

KEYWORDS

Acute kidney disease; inhospital mortality; elderly patients; machine learning; noninvasive parameters

Introduction

Acute kidney injury (AKI), a complex public health concern affecting ~15% of patients in hospitals and 40% in intensive care units (ICUs), is associated with a high incidence of adverse events with organ involvement [1–3]. As a result of changes in kidney structure, more comorbidities, and greater susceptibility to renal injury, the morbidity and mortality of elderly patients with AKI are higher than in younger groups [4,5]. In 2017, the Acute Disease Quality Initiative (ADQI) 16 workgroup defined acute kidney disease (AKD) as recurrent renal impairment within 7–90 days of the AKI diagnosis [6]. As a novel concept in the field of kidney disease, AKD presents considerable potential for clinical research during the transitional period between AKI and chronic kidney disease (CKD) [7]. About half of patients with AKI might progress to AKD [8]. Meanwhile, the risk of death associated with AKD in ICU was approximately twice that of AKI patients [9]. Furthermore, 60% of patients in ICU were over 65 years old, reflecting the aging process of the inpatient population [10]. Being the primary focus of health care, the elderly deserve more urgent attention. Therefore, it is necessary to conduct population characterization and construct a reliable and accessible web-based tool to assess the prognosis for AKD in the elderly, which may provide a critical window for early targeted interventions.

Recently, clinical interest has gradually been drawn to research on predictive prognosis for AKD, while enthusiasm for research on AKI remains strong. There have been several studies conducted to predict AKD in patients with sepsis, post-nephrectomy, or post-cardiac surgery, with high predictive performance [11–13]. In

CONTACT Shuangping Zhao 🖾 zhshping@csu.edu.cn 🖃 No.87, Xiangya Road, Kaifu District, Changsha 410008, Hunan, China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

addition, a prospective study found that urinary neutrophil gelatinase-associated lipocalin could be used as a biomarker of long-term survival of patients with AKD admitted to coronary care units [14]. Xiao et al. proposed a prognostic early warning model for hospitalized AKD patients based on the traditional logistic regression method [15]. Furthermore, Yan et al. have developed a neural network-based model to predict AKI in patients with CKD following the administration of iodinated contrast media, which has superior prediction accuracy than logical regression, but the researchers did not construct online applications for further assessment [16]. However, there are some inconveniences in operation, limited repeatability, or lack of external validation regardless of whether the model is traditional statistically or machinelearning based. Also, biomarkers have limitations similar to laboratory indicators, such as difficult acquisition, high costs, and delayed results.

Accordingly, we aimed to develop a web-based tool for predicting in-hospital mortality of AKD in the elderly based on machine learning algorithms with high accuracy and noninvasive parameters with easy access and adjustment, and further to perform external validation to demonstrate the generalization of the tool. Moreover, we employed SHAP to visualize the features in order to determine optimal thresholds for early clinical decision-making to enhance short-term outcomes.

Methods

Study design and cohort extraction

This was a multicenter retrospective cohort study based on large electronic medical records datasets. We included patients older than or equal to 60 years of age, according to the definition of the elderly in China. The exclusion criteria were as follows: (1) length of stay in ICU <48 h; (2) repeated admissions to ICU; (3) end-stage renal disease (ESRD); (4) no AKI or missing diagnosis data; (5) no AKD missing diagnosis data. In accordance with inclusion and exclusion criteria, information on AKD in elderly individuals was extracted from the following critical care databases: the Medical Information Mart for Intensive Care IV (MIMIC-IV, version 1.0) originated from a single-center hospital and the eICU Collaborative Research Database (elCU-CRD, version 2.0) from multicenter hospitals [17,18]. We used the MIMIC-IV cohort for model training and the elCU-CRD cohort for external validation. It has been granted access to the MIMIC-IV and elCU-CRD databases (record ID: 41817305). Our study was exempted from approval by the Institutional Review Board due to the deprivation of the data. We adhered to the Declaration of Helsinki and the Statement of the

Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis [19,20].

Noninvasive parameters collection

Noninvasive parameters with broad access and easy intervention were used as predictors of mortality in elderly patients with AKD, as follows: (1) basic demographics: age, gender, ethnicity, and body mass index (BMI); (2) severity of disease: AKI stage, Glasgow coma scale (GCS) and sequential organ failure assessment (SOFA); (3) comorbidities: sepsis, hypertension, diabetes mellitus, cerebrovascular disease, congestive heart failure (CHF), and CKD; (4) interventions: mechanical ventilation (MV), renal replacement therapy (RRT), and vasopressor use; (5) the worst value of noninvasive vital signs monitoring: heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), temperature, respiratory rate, and peripheral oxygen saturation (SpO2). The above-mentioned features were extracted from the day of ICU admission. In addition, regarding the GCS, SOFA, and noninvasive monitoring of vital signs, we also identified the changes between the worst value on the day of AKD diagnosis and ICU admission, that is, the fluctuation range of these indicators as modeling features, including delta GCS, delta SOFA, delta heart rate, delta SBP, delta DBP, delta MAP, delta temperature, delta respiratory rate, and delta SpO2.

AKD definition

AKI was diagnosed and staged based on serum creatinine and urine output according to the Kidney Disease: Improving Global Outcomes guidelines for the diagnosis and management of AKI in 2012 [21]. Patients with AKD were diagnosed on the basis of the ADQI 16 workgroup consensus in 2017, which required AKI with at least stage I within 7–90 days after the initial diagnosis of AKI or before discharge [6]. In addition, the primary outcome of our study was in-hospital mortality in the elderly with AKD, which served as the predictive endpoint of our model.

Baseline creatinine was determined by the lowest normal creatinine level during hospitalization, which also applied to patients with CKD with a higher baseline creatinine level than normal. Otherwise, we used the Modification of Diet in Renal Disease Trial formula to estimate the baseline creatinine.

Machine learning algorithms

By analyzing massive amounts of information and identifying patterns, machine learning algorithms can make intelligent predictions on newly acquired data. A total of five supervised machine learning algorithms [logistic regression model (LRM), random forest (RF), extreme gradient boosting (XGBoost), multilayer perceptron (MLP), support vector machine (SVM)] were selected to predict categorical labels. Modeling was conducted using the MIMIC-IV cohort, and external validation was carried out using the elCU-CRD cohort as a new dataset. In order to prevent overfitting and enhance generalizability, a grid search was carried out with 10-fold crossvalidation to tune the parameters of the classifier, and further predictions were made to an independent dataset. On the basis of the optimal cutoff value under various algorithms, we obtained the area under the receiver operating characteristic (ROC) curve (AUC), precision-recall curves, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to evaluate classification models. Further, calibration curves were drawn for the training and validation cohorts to assess the agreement of the predicted and actual probabilities, as well as decision curves to analyze the clinical utility. The SHapley Additive Explanation (SHAP) enhanced the interpretability of machine learning models by visualizing the marginal contributions of individual features and displaying partial dependence plots to demonstrate how features contribute to and interfere with the death risk in the elderly with AKD. Finally, we selected the best-performing model from external validation for the development, and deployment of a simplified online application with the top 10 features from importance ranking.

Statistical analysis

All statistical analyses were conducted using Python (version 3.9.7) and R (version 4.2.0) software. Statistical significance was set as a two-sided P value <0.05. The continuous variables conforming to a normal distribution were represented by the mean (standard deviation) and tested by the two-tailed *t*-test, while non-normally distributed variables were expressed as the median (interquartile range) and analyzed by the Mann-Whitney U-test. Furthermore, categorical variables are presented as numbers (percentages) and analyzed using the χ^2 test. The missing values were multiply imputed by the mice package (version 3.14.0) of R software. The features selected for this study were noninvasive parameters readily available to clinicians, so there were no features with a missing ratio exceeding 20% to be removed.

Results

Baseline characteristics of AKD in the elderly

In this retrospective study, we finally enrolled 2666 elderly patients with AKD from the MIMIC-IV and 535 from the eICU-CRD as training and external validation datasets for the machine learning model, respectively. A detailed description of the screening process for patients is shown in Figure 1. After removing missing follow-up data from the MIMIC-IV cohort, 75.2% (2666/ 3547) of AKI in the elderly progressed to AKD, of whom 29.6% (790/2666) died in the hospital. Moreover, an externally validated cohort from the elCU-CRD showed an incidence of 55.6% (535/962) and in-hospital mortality of 31.8% (170/535) for elderly patients with AKD (Figure 1). According to Table 1, baseline characteristics of the two cohorts were presented, stratified by the presence or absence of in-hospital death in aged individuals with AKD. Patients with AKD who died in hospital were found to be older, have lower BMI, and be less likely to be white in terms of demographics; to have lower GCS, higher delta GCS, SOFA, and delta SOFA in terms of disease severity; to have a higher proportion of sepsis and CKD and a lower proportion of hypertension in terms of comorbidities; to be receiving more RRT and vasopressors in terms of interventional therapy; to have higher heart rate and respiratory rate and lower delta heart rate, SBP, delta SBP, DBP, delta DBP, MAP, delta MAP, temperature, delta respiratory rate, and delta SpO2 in terms of vital signs (p < 0.05). Furthermore, some features in the elCU-CRD cohort shared similar trends and statistical significance with the MIMIC-IV cohort, including age, BMI, sepsis, SBP, delta SBP, DBP, MAP, delta MAP, temperature, and delta SpO2 (*P* < 0.05).

Performance comparison of models with machine learning algorithms

As all of the variables shown in Table 1 are noninvasive and readily available in clinical practice, we incorporated all of the parameters into the development of models. The performance comparison of six machine learning models for predicting mortality of elderly patients with AKD in the training and external validation cohorts is presented in Table 2. For each algorithm in the training cohort, we performed a 10-fold cross-validation grid search to determine the optimal hyperparameters (Additional file 1), resulting in the model with the highest prediction accuracy, which was then evaluated in the testing cohort. The best prediction performance in the training cohort was achieved



Figure 1. A flowchart for the selection of elderly patients with AKD. AKD: acute kidney disease; AKI: acute kidney injury; elCU-CRD: the elCU Collaborative Research Database; ESRD: end-stage renal disease; ICU: intensive care unit; MIMIC-IV: medical information mart for intensive care IV.

by XGBoost, which had an AUC of 0.899 (0.884-0.914), a sensitivity of 0.799 (0.769-0.826), a specificity of 0.830 (0.812–0.847), a PPV of 0.664 (0.633–0.694), and an NPV of 0.907 (0.893–0.921). Furthermore, in the external validation cohort, the simplified model based on SVM using the top 10 features demonstrated good discrimination for AKD in the elderly survivors, as indicated by an AUC of 0.776 (0.731-0.821), a sensitivity of 0.738 (0.666-0.802), a specificity of 0.686 (0.635-0.733), a PPV of 0.527 (0.462-0.591), and an NPV of 0.846 (0.801-0.886) (Table 2). The ROC curves for the six classification models are shown in Figure 2a,b, in which the model with the simplified model with SVM performed well in training and external validation cohorts. To illustrate the relative accuracy and clinical utility of the predictive models, we selected two models (SVM and

simplified SVM) that performed better in the validation process to draw calibration curves; precision-recall curves conduct decision curve analysis (Figure 3).

Interpretation and visualization of SVM predictions

To better explain the clinical significance of certain variables, we utilized SHAP to visualize predictions generated by the machine learning model. As shown in Figure 4a, the risk of in-hospital mortality in elderly with AKD was positively associated with the following features: delta SOFA, SOFA, sepsis, age, vasopressor use, MV, respiratory rate, heart rate, delta DBP, renal toxic drugs, race other than white, and female. Moreover, we have drawn the ranking plot of feature importance

Table 1. Baseline characteristics of elderly patients with A	KD.
--------------------------------------------------------------	-----

$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		Τ	raining cohort		External validation cohort		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Variables	Survival (<i>n</i> = 1876)	Death (<i>n</i> = 790)	P-value	Survival (<i>n</i> = 363)	Death (<i>n</i> = 172)	P-value
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Demographic						
	Age, years	72.7 [66.6, 80.1]	76.1 [68.7, 82.8]	< 0.001	70.0 [64.0, 75.0]	72.0 [66.0, 79.0]	0.002
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Gender, n (%)			0.131			0.569
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Male	1087 (57.9)	432 (54.7)		200 (55.1)	100 (58.1)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Female	789 (42.1)	358 (45.3)		163 (44.9)	72 (41.9)	
	Ethnicity, n (%)			0.015			0.006
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	White	1275 (68.0)	517 (65.4)		264 (72.7)	147 (85.5)	
$\begin{array}{ccccc} Asian & 48 (2.6) & 14 (1.8) & 3 (0.8) & 1 (0.6) \\ Other & 357 (19.0) & 190 (24.1) & 36 (9.9) & 13 (7.6) \\ BMI (kg/m^2) & 29.0 [24.8, 34.2] & 27.7 [23.8, 33.0] & <0.001 & 29.9 [25.8, 36.0] & 28.3 [24.6, 33.5] & 0.01 \\ Disease severity & & & & & & & & & & & & & & & & & & &$	Black	196 (10.4)	69 (8.7)		60 (16.5)	11 (6.4)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Asian	48 (2.6)	14 (1.8)		3 (0.8)	1 (0.6)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Other	357 (19.0)	190 (24.1)		36 (9.9)	13 (7.6)	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	BMI (kg/m ²)	29.0 [24.8, 34.2]	27.7 [23.8, 33.0]	< 0.001	29.9 [25.8, 36.0]	28.3 [24.6, 33.5]	0.018
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Disease severity						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Aki stage, n (%)			0.583			0.141
II $389 (20.7)$ $178 (22.5)$ $58 (16.0)$ $18 (10.5)$ III $35 (1.9)$ $14 (1.8)$ $4 (1.1)$ $4 (2.3)$ GCS $10.0 [6.0, 13.0]$ $7.0 [3.0, 11.0]$ <0.001 $8.0 [3.0, 13.0]$ $8.0 [3.0, 13.0]$ 0.75 Delta GCS $5.0 [2.0, 9.0]$ $7.0 [4.0, 12.0]$ <0.001 $4.0 [0.0, 8.0]$ $1.0 [-2.0, 5.0]$ <0.000 SOFA $8.0 [5.0, 11.0]$ $9.0 [7.0, 12.0]$ <0.001 $8.0 [5.0, 10.0]$ $7.0 [5.0, 10.0]$ 0.38 Delta SOFA $-2.0 [-4.0, 0.0]$ $0.0 [-3.0, 1.8]$ <0.001 $-1.0 [-4.0, 1.0]$ $1.0 [-1.2, 4.0]$ <0.000 Comorbidities, n (%)Sepsis $1706 (90.9)$ $756 (95.7)$ <0.001 $107 (29.5)$ $71 (41.3)$ 0.00 Hypertension $964 (51.4)$ $372 (47.1)$ 0.047 $60 (16.5)$ $33 (19.2)$ 0.52 Diabetes mellitus $757 (40.4)$ $291 (36.8)$ 0.098 $53 (14.6)$ $35 (20.3)$ 0.12 Cerebrovascular disease $116 (6.2)$ $37 (4.7)$ 0.153 $35 (9.6)$ $9 (5.2)$ 0.11 CHF $435 (23.2)$ $201 (25.4)$ 0.231 $45 (12.4)$ $30 (17.4)$ 0.15 CKD $554 (29.5)$ $273 (34.6)$ 0.012 $45 (12.4)$ $20 (17.4)$ 0.15 MV $1849 (98.6)$ $780 (98.7)$ 0.866 $65 (17.9)$ $44 (25.6)$ 0.05 RRT $311 (16.6)$ $228 (28.9)$ <0.001 $9 (2.5)$ $2 (1.2)$ 0.49 Renal toxic drugs $1811 ($	I -	1452 (77.4)	598 (75.7)		301 (82.9)	150 (87.2)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	I	389 (20.7)	178 (22.5)		58 (16.0)	18 (10.5)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	III	35 (1.9)	14 (1.8)		4 (1.1)	4 (2.3)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	GCS	10.0 [6.0, 13.0]	7.0 [3.0, 11.0]	< 0.001	8.0 [3.0, 13.0]	8.0 [3.0, 13.0]	0.75
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Delta GCS	5.0 [2.0, 9.0]	7.0 [4.0, 12.0]	< 0.001	4.0 [0.0, 8.0]	1.0 [-2.0, 5.0]	< 0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	SOFA	8.0 [5.0, 11.0]	9.0 [7.0, 12.0]	< 0.001	8.0 [5.0, 10.0]	7.0 [5.0, 10.0]	0.385
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Delta SOFA	-2.0 [-4.0, 0.0]	0.0 [-3.0, 1.8]	< 0.001	-1.0 [-4.0, 1.0]	1.0 [-1.2, 4.0]	< 0.001
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comorbidities, n (%)						
Hypertension964 (51.4)372 (47.1)0.04760 (16.5)33 (19.2)0.52Diabetes mellitus757 (40.4)291 (36.8)0.09853 (14.6)35 (20.3)0.12Cerebrovascular disease116 (6.2)37 (4.7)0.15335 (9.6)9 (5.2)0.11CHF435 (23.2)201 (25.4)0.23145 (12.4)30 (17.4)0.15CKD554 (29.5)273 (34.6)0.01245 (12.4)26 (15.1)0.46Interventions, n (%)NV1849 (98.6)780 (98.7)0.86665 (17.9)44 (25.6)0.05RRT311 (16.6)228 (28.9)<0.001	Sepsis	1706 (90.9)	756 (95.7)	< 0.001	107 (29.5)	71 (41.3)	0.009
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hypertension	964 (51.4)	372 (47.1)	0.047	60 (16.5)	33 (19.2)	0.525
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Diabetes mellitus	757 (40.4)	291 (36.8)	0.098	53 (14.6)	35 (20.3)	0.121
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Cerebrovascular disease	116 (6.2)	37 (4.7)	0.153	35 (9.6)	9 (5.2)	0.118
CKD 554 (29.5) 273 (34.6) 0.012 45 (12.4) 26 (15.1) 0.46 Interventions, n (%) MV 1849 (98.6) 780 (98.7) 0.866 65 (17.9) 44 (25.6) 0.05 RRT 311 (16.6) 228 (28.9) <0.001	CHF	435 (23.2)	201 (25.4)	0.231	45 (12.4)	30 (17.4)	0.151
Interventions, n (%) MV 1849 (98.6) 780 (98.7) 0.866 65 (17.9) 44 (25.6) 0.05 RRT 311 (16.6) 228 (28.9) <0.001	CKD	554 (29.5)	273 (34.6)	0.012	45 (12.4)	26 (15.1)	0.466
MV 1849 (98.6) 780 (98.7) 0.866 65 (17.9) 44 (25.6) 0.05 RRT 311 (16.6) 228 (28.9) <0.001	Interventions, n (%)						
RRT 311 (16.6) 228 (28.9) <0.001 9 (2.5) 2 (1.2) 0.49 Renal toxic drugs 1811 (96.5) 767 (97.1) 0.541 54 (14.9) 46 (26.7) 0.00 Vasopressor use 1388 (74.0) 683 (86.5) <0.001	MV	1849 (98.6)	780 (98.7)	0.866	65 (17.9)	44 (25.6)	0.052
Renal toxic drugs 1811 (96.5) 767 (97.1) 0.541 54 (14.9) 46 (26.7) 0.00 Vasopressor use 1388 (74.0) 683 (86.5) <0.001	RRT	311 (16.6)	228 (28.9)	< 0.001	9 (2.5)	2 (1.2)	0.499
Vasopressor use 1388 (74.0) 683 (86.5) <0.001 124 (34.2) 56 (32.6) 0.78 Vital signs Heart rate (bpm) 85.1 [77.0, 94.3] 88.0 [78.4, 97.5] <0.001	Renal toxic drugs	1811 (96.5)	767 (97.1)	0.541	54 (14.9)	46 (26.7)	0.002
Vital signs Heart rate (bpm) 85.1 [77.0, 94.3] 88.0 [78.4, 97.5] <0.001 91.3 [80.4, 104.8] 88.9 [77.6, 98.6] 0.01 Delta heart rate (bpm) -15.7 [-23.0, -8.6] -17.9 [-30.1, -8.4] <0.001	Vasopressor use	1388 (74.0)	683 (86.5)	< 0.001	124 (34.2)	56 (32.6)	0.789
Heart rate (bpm) 85.1 [77.0, 94.3] 88.0 [78.4, 97.5] <0.001 91.3 [80.4, 104.8] 88.9 [77.6, 98.6] 0.01 Delta heart rate (bpm) -15.7 [-23.0, -8.6] -17.9 [-30.1, -8.4] <0.001	Vital signs						
Delta heart rate (bpm) -15.7 [-23.0, -8.6] -17.9 [-30.1, -8.4] <0.001 -21.8 [-34.3, -9.1] -17.2 [-26.8, -6.4] 0.00	Heart rate (bpm)	85.1 [77.0, 94.3]	88.0 [78.4, 97.5]	< 0.001	91.3 [80.4, 104.8]	88.9 [77.6, 98.6]	0.01
	Delta heart rate (bpm)	-15.7 [-23.0, -8.6]	-17.9 [-30.1, -8.4]	< 0.001	-21.8 [-34.3, -9.1]	-17.2 [-26.8, -6.4]	0.002
SBP (mmHg) 118.1 [109.5, 129.4] 112.7 [105.6, 123.2] <0.001 116.0 (17.9) 115.0 (15.1) 0.49	SBP (mmHg)	118.1 [109.5, 129.4]	112.7 [105.6, 123.2]	< 0.001	116.0 (17.9)	115.0 (15.1)	0.499
Delta SBP (mmHg) -27.7 [-38.0, -19.3] -33.1 [-46.6, -22.5] <0.001 -20.1 [-34.3, -3.2] -28.6 [-43.0, -13.8] <0.00	Delta SBP (mmHg)	-27.7 [-38.0, -19.3]	-33.1 [-46.6, -22.5]	< 0.001	-20.1 [-34.3, -3.2]	-28.6 [-43.0, -13.8]	< 0.001
DBP (mmHg) 59.2 [54.2, 65.1] 57.0 [52.1, 62.4] <0.001 62.7 [56.3, 69.8] 60.3 [55.4, 66.3] 0.00	DBP (mmHg)	59.2 [54.2, 65.1]	57.0 [52.1, 62.4]	< 0.001	62.7 [56.3, 69.8]	60.3 [55.4, 66.3]	0.003
Delta DBP (mmHg) -16.2 [-21.8, -11.3] -18.5 [-24.9, -12.7] <0.001 -15.5 [-25.2, -8.8] -17.3 [-27.3, -10.5] 0.13	Delta DBP (mmHg)	-16.2 [-21.8, -11.3]	-18.5 [-24.9, -12.7]	< 0.001	-15.5 [-25.2, -8.8]	-17.3 [-27.3, -10.5]	0.139
MAP (mmHg) 76.4 [71.6, 82.5] 73.3 [69.4, 79.0] <0.001 76.9 [68.7, 84.7] 74.5 [67.7, 81.4] 0.03	MAP (mmHg)	76.4 [71.6, 82.5]	73.3 [69.4, 79.0]	< 0.001	76.9 [68.7, 84.7]	74.5 [67.7, 81.4]	0.035
Delta MAP (mmHg) -20.0 [-26.5, -13.9] -22.4 [-32.0, -16.2] <0.001 -16.2 [-25.4, -6.6] -18.3 [-29.1, -9.4] 0.02	Delta MAP (mmHg)	-20.0 [-26.5, -13.9]	-22.4 [-32.0, -16.2]	< 0.001	-16.2 [-25.4, -6.6]	-18.3 [-29.1, -9.4]	0.023
Temperature (°C) 37.0 (0.5) 36.9 (0.5) <0.001 37.0 [36.7, 37.3] 36.7 [36.4, 37.2] 0.00	Temperature (°C)	37.0 (0.5)	36.9 (0.5)	< 0.001	37.0 [36.7, 37.3]	36.7 [36.4, 37.2]	0.001
Delta Temperature (°C) -0.6 [-0.9, -0.3] -0.6 [-1.0, -0.3] 0.516 -0.6 [-1.1, -0.2] -0.4 [-1.0, 0.0] 0.06	Delta Temperature (°C)	-0.6 [-0.9, -0.3]	-0.6 [-1.0, -0.3]	0.516	-0.6 [-1.1, -0.2]	-0.4 [-1.0, 0.0]	0.063
Respiratory rate (bpm) 20.3 (3.1) 21.0 (3.4) <0.001 19.8 [17.2, 23.3] 20.0 [17.4, 24.0] 0.35	Respiratory rate (bpm)	20.3 (3.1)	21.0 (3.4)	< 0.001	19.8 [17.2, 23.3]	20.0 [17.4, 24.0]	0.359
Delta Respiratory rate (bpm) -7.1 [-9.7, -4.9] -7.8 [-11.2, -5.3] <0.001 -6.7 [-10.9, -3.0] -5.1 [-10.2, -1.6] 0.03	Delta Respiratory rate (bpm)	-7.1 [-9.7, -4.9]	-7.8 [-11.2, -5.3]	< 0.001	-6.7 [-10.9, -3.0]	-5.1 [-10.2, -1.6]	0.038
SpO2 (%) 96.9 [95.9, 97.9] 97.0 [95.8, 97.9] 0.958 96.9 [95.2, 98.2] 96.9 [95.2, 98.7] 0.34	SpO2 (%)	96.9 [95.9, 97.9]	97.0 [95.8, 97.9]	0.958	96.9 [95.2, 98.2]	96.9 [95.2, 98.7]	0.345
Delta SpO2 (%) -5.1 [-7.3, -3.2] -6.3 [-12.7, -3.8] <0.001 -4.9 [-8.5, -2.0] -7.0 [-14.9, -3.4] <0.00	Delta SpO2 (%)	-5.1 [-7.3, -3.2]	-6.3 [-12.7, -3.8]	< 0.001	-4.9 [-8.5, -2.0]	-7.0 [-14.9, -3.4]	< 0.001

AKI: acute kidney injury; CHF: congestive heart failure; CKD: chronic kidney disease; DBP: diastolic blood pressure; GCS: Glasgow coma scale; MAP: mean artery pressure; MV: mechanical ventilation; RRT: renal replacement therapy; SBP: systolic blood pressure; SOFA: sequential organ failure assessment; SpO2: peripheral oxygen saturation.

(Figure 4b), as well as partial dependency plots for the relationship between the SHAP value and the feature value for the 12 most important continuous parameters (Figure 5). An analysis of partial dependence plots can provide a visual interpretation of the distribution of each feature and its global relationship to in-hospital mortality. Figure 5a illustrated how delta SOFA affected the risk of death. As delta SOFA gradually increased from -1, the death risk also gradually increased from 0, indicating the optimal cutoff value for delta SOFA was -1. Similar patterns can also be observed with SOFA (cutoff 7; Figure 5e), age (cutoff 75; Figure 5i),

respiratory rate (cutoff 22; Figure 5k), and heart rate (cutoff 90; Figure 5l). In addition, the probability of dying in the hospital increased as GCS decreased from 10 (Figure 5b). The following features also displayed opposite trends: delta GCS (cutoff 5; Figure 5c), delta SpO2 (cutoff -10; Figure 5d), delta SBP (cutoff -25; Figure 5f), MAP (cutoff 75; Figure 5g), delta MAP (cutoff -20; Figure 5h), and SBP (cutoff 120; Figure 5j). Targeted management of vital signs based on the cutoff values shown in the partial dependence plots may contribute to controlling and minimizing the in-hospital death risk of AKD in the elderly.

Table 2. The predictive performance of models in the training and external validation cohorts.

			1	Fraining cohort		
Models	AUC	Cutoff	Sensitivity	Specificity	PPV	NPV
LRM	0.812 (0.793-0.832)	0.335	0.673 (0.639–0.706)	0.809 (0.790-0.826)	0.597 (0.564–0.629)	0.855 (0.837-0.871)
RF	0.855 (0.838-0.873)	0.316	0.697 (0.663-0.728)	0.845 (0.828-0.861)	0.653 (0.621-0.686)	0.868 (0.852-0.884)
XGBoost	0.899 (0.884-0.914)	0.315	0.799 (0.769–0.826)	0.830 (0.812-0.847)	0.664 (0.633-0.694)	0.907 (0.893-0.921)
MLP	0.824 (0.805-0.843)	0.356	0.675 (0.641-0.707)	0.821 (0.803-0.838)	0.613 (0.580-0.646)	0.857 (0.840-0.873)
SVM	0.823 (0.804-0.842)	0.295	0.722 (0.689–0.753)	0.787 (0.768-0.806)	0.588 (0.557-0.619)	0.870 (0.853-0.886)
Simplified SVM	0.810 (0.790-0.830)	0.271	0.713 (0.680–0.744)	0.768 (0.748–0.787)	0.564 (0.532–0.595)	0.864 (0.846-0.880)
	External validation cohort					
Models	AUC	Cutoff	Sensitivity	Specificity	PPV	NPV
LRM	0.739 (0.691–0.786)	0.293	0.634 (0.557–0.706)	0.733 (0.684–0.778)	0.529 (0.459–0.599)	0.809 (0.762-0.850)
RF	0.689 (0.639-0.739)	0.273	0.663 (0.587-0.733)	0.651(0.599-0.699)	0.473 (0.409-0.538)	0.803 (0.753-0.847)
XGBoost	0.716 (0.668-0.765)	0.246	0.622 (0.545-0.695)	0.738 (0.690-0.783)	0.530 (0.458-0.600)	0.805 (0.758-0.846)
MLP	0.731 (0.683-0.779)	0.323	0.610 (0.533-0.684)	0.755(0.707-0.798)	0.541 (0.468-0.613)	0.804 (0.757-0.844)
SVM	0.759 (0.713-0.805)	0.337	0.634 (0.557-0.706)	0.796 (0.751-0.836)	0.595 (0.521-0.667)	0.821 (0.777-0.860)
Simplified SVM	0.776 (0.731–0.821)	0.238	0.738 (0.666–0.802)	0.686 (0.635–0.733)	0.527 (0.462–0.591)	0.846 (0.801–0.886)

AUC: the area under the receiver operating characteristic curve; LRM: logistic regression model; MLP: multilayer perceptron; NPV: negative predictive value; PPV: positive predictive value; RF: random forest; SVM: support vector machine; XGBoost: extreme gradient boosting.

Additional file 1. The optimal hyperparameters for five models based on the ten-fold cross-validation.

Models	Hyperparameters	Settings
LRM	С	0.248
	max_iter	100000
	solver	liblinear
RF	max_depth	9
	max_features	10
	min_samples_leaf	8
	min_samples_split	4
XGBoost	gamma	0.2
	max_depth	4
	min_child_weight	6
	max_delta_step	0
MLP	kernel_initializer	uniform
	activation	hard_sigmoid
SVM	С	1000
	gamma	0.0001
	kernel	rbf
Simplified SVM	С	100
-	gamma	0.001
	kernel	rbf

LRM: logistic regression model; MLP: multilayer perceptron; RF: random forest; SVM: support vector machine; XGBoost: extreme gradient boosting.

A user-friendly web-based tool for predicting in-hospital mortality in elderly patients with AKD

We finally selected the simplified SVM model using only 10 features for deployment in light of the predictive performance of various machine learning algorithms in the external validation cohort (Figure 2b), developing a readily accessible online tool for clinicians to predict inhospital mortality of AKD in the elderly (https://forlmx. herokuapp.com/). In different clinical practice settings, once an elderly patient has been diagnosed with AKD, physicians can quickly collect and enter values for noninvasive parameters into the web application, and then click on the 'predict' button to obtain a prediction of in-hospital survival. The partial dependence plots in Figure 5 allowed us to treat patients at risk of death as early as possible and to control the intervenable indicators near the cutoff value, which has practical value for guiding physicians to save lives.

Discussion

In this retrospective study using multicenter critical care data, we developed and externally validated a predictive model based primarily on noninvasive parameters for elderly patients with AKD, and then selected the best performing simplified model with SVM algorithm (AUC in the training set: 0.810 (0.790–0.830); AUC in the testing set: 0.776 (0.731–0.821)) to deploy a web-based prediction tool. According to our knowledge, this is the first prognostic study and online prediction application developed for elderly patients with AKD. More importantly, the online tool can identify patients at risk of inhospital death on the diagnosis of AKD, allowing a larger window of time for physicians and patients to intervene.

In 2017, the ADQI 16 workgroup released an expert consensus on AKD for the first time and emphasized the need for clinical research in this area [6]. According to previous studies, ~45% of patients with AKI progressed to AKD with in-hospital mortality of ~26%, significantly greater than ~12% in patients without AKD [8,9]. As a result of increased susceptibility factors to renal injury, the elderly experience higher morbidity and mortality from AKI [22]. Our study demonstrated that 29.6% and 31.8% of AKD in the elderly died in the hospital in the MIMIC-IV and eICU-CRD cohorts, respectively, which were higher than 26.1% in adults with AKD and 24.6% in sepsis with AKD from other studies [9,23]. As well, we found that in older patients with AKD, the stage of initial AKI was not associated with in-hospital mortality, similar to the multicenter study conducted by Peng et al. on AKI in the elderly [24]. Meanwhile, short-



Figure 2. (a) The ROC curves of the SVM, Simplified SVM, LRM, MLP, RF, and XGB in the training cohort. (b) The ROC curves of the SVM, Simplified SVM, LRM, MLP, RF, and XGB in the external validation cohort. LRM: logistic regression model; MLP: multilayer perceptron; RF: random forest; SVM: support vector machine; XGBoost: extreme gradient boosting.



Figure 3. (a) Calibration curves. (b) Decision curve analysis. (c) Precision-Recall curves of the SVM and Simplified SVM in the external validation cohort. SVM: support vector machine.

and long-term mortality was also independent of the level of AKI severity in sepsis with AKD [25].

A majority of laboratory indicators are not available on a daily basis as a result of invasive monitoring procedures and high measurement costs. Noninvasive parameters such as vital signs can be collected more conveniently and respond more sensitively to changes in the patient's condition. Zhang et al. applied only the indicators of noninvasive monitoring to establish an outcome prediction model for general critically ill patients, and the performance was no less than that of the model incorporating laboratory indicators [26]. In addition, we found that the fluctuation ranges of certain indicators between the day of ICU admission and the diagnosis of AKD have a high predictive value and corresponding cutoff values, including delta SOFA, delta GCS, delta SpO2, delta SBP, and delta MAP. Controlling the change in indicators within the threshold range may benefit the prognosis of elderly patients with AKD. He et al. used the magnitude of SOFA change as a feature for predicting AKD in septic patients, but the delta SOFA was the difference between day 3 and day 1

without taking into account the condition at the time of AKI diagnosis [11]. Karakike et al. demonstrated that the difference in SOFA between day 7 and admission may be a reliable predictor of short-term mortality in sepsis [27]. However, no exploratory studies have been carried out on the optimal thresholds for SOFA changes at different periods of time.

GCS, SOFA, MAP, and sepsis have also been identified as critical predictors of short-term survival for elderly patients with AKD. As a measure of the level of consciousness disturbance, GCS is commonly used to assess patients with cerebrovascular disease and traumatic brain injury (TBI). A multicenter observational study showed that GCS was a critical predictor of death in hospitalization in patients with TBI [28]. Abdallah et al. reported a higher risk of 30-day mortality among adult patients with GCS of 8 or less in the emergency department [29]. In our study, we observed that GCS was inversely related to the in-hospital death risk of AKD in elderly individuals, with a critical threshold of 10 for GCS. In addition, we found that SOFA \geq 7 may increase the risk of mortality for individuals with AKD, in line with



Figure 4. (a) The distribution of the impacts of features on the SVM model. (b) The ranking of features importance. DBP: diastolic blood pressure; GCS: Glasgow coma scale; MAP: mean artery pressure; MV: mechanical ventilation; SBP: systolic blood pressure; SpO2: peripheral oxygen saturation; SOFA: sequential organ failure assessment.



Figure 5. The partial dependence plots of (a) Delta SOFA, (b) GCS, (c) Delta GCS, (d) Delta SpO2, (e) SOFA, (f) Delta SBP, (g) MAP, (h) Delta MAP, (i) Age, (j) SBP, (k) Respiratory rate, and (l) Heart rate. GCS: Glasgow coma scale; MAP: mean artery pressure; SBP: systolic blood pressure; SOFA: sequential organ failure assessment; SpO2: peripheral oxygen saturation.

previous studies indicating that SOFA was significantly associated with the prognosis of severe illnesses such as sepsis, surgery, and acute decompensated heart failure [30-32]. MAP is an essential part of hemodynamic monitoring, and the optimal threshold for treatment has been widely debated. The Surviving Sepsis Campaign Guidelines in 2021 recommended an optimal MAP target of 65 mmHg for patients with septic shock [33]. However, Maheshwari et al. demonstrated that this target setting of MAP may be prudent, since their retrospective analysis of multicenter data from 110 hospitals revealed that the in-hospital mortality of patients with sepsis increased as MAP decreased from 85 mmHg [34]. A prospective study showed that septic patients with MAP lower than 73 mmHg were more susceptible to AKI [35]. In our study, the optimal cutoff value for MAP was determined to be 75 mmHg to promote short-term survival for elderly patients with AKD. In the ICU, sepsis is the leading cause of AKI, and mortality from sepsis-associated AKI can reach 60% [36]. In a large randomized controlled trial, there was no indication that septic shock patients with AKD increased the risk of in-hospital death by 60-day and the length of ICU stay [37]. Nevertheless, our study revealed that sepsis was an independent death risk factor for people with AKD, possibly due to the broader focus on older adults.

While many studies have investigated the use of machine learning algorithms to predict prognosis, only a few have developed easy-to-use predictive tools to alert caregivers to timely interventions. In a clusterrandomized trial of multifaceted interventions in patients with AKI, an organized intervention could improve the accuracy of diagnosis and reduce the length of stay in the hospital [38]. Researchers have demonstrated the clinical value of an early warning system for AKI in identifying patients at high risk of morbidity and mortality [39]. Recently, Peng et al. have established an all-cause mortality score formula for predicting short-term survival of elderly hospitalized patients with AKI, which can be used to determine the individual death risk by adding up the scores represented by different variables [24]. However, there is currently no study on early warning of AKD in the elderly. The web-based prediction tool we developed is externally validated and can easily be deployed in any healthcare setting to guide clinicians in early intervention planning (https://forlmx.herokuapp.com/).

There are some limitations to our study. First, due to the fact that AKD was not diagnosed until 7 days after the initial event of AKI, we excluded patients who were discharged within 7 days of the diagnosis from the cohorts, since only hospitalization data was available. Second, the online prediction tool developed using multiple classifier algorithms can identify whether elderly patients with AKD are at risk of death. Therefore, the probability of death cannot be displayed in detail. Further, we are only able to predict survival when patients have been discharged from the hospital based on the available datasets, since survival data for long-term follow-up was lacking. Last, we performed external validation with the elCU-CRD cohort from the multicenter and achieved good performance. However, prospective intervention trials based on local medical record system will be necessary to determine the extent to which web prediction tools can contribute to improving the prognosis of AKD in elderly individuals as compared to clinical experience alone.

Conclusions

In conclusion, we constructed six models for predicting in-hospital mortality of AKD in the elderly with noninvasive parameters including demographics, comorbidities, vital signs, and corresponding fluctuation differences. For generalization to different medical settings, the simplified SVM with the highest performance in the external validation cohort was selected for deployment as an online tool. As well, the predictions of the web tool combined with the optimal thresholds in the partial dependence plots have the potential to advance bundled management to improve prognosis in elderly patients with AKD.

Acknowledgements

We are grateful to the authors of the MIMIC-IV and elCU-CRD databases, which have contributed greatly to the advancement of clinical research.

Ethics approval and consent to participate

Not applicable.

Author contributions

Study design: Shuangping Zhao and Chenghuan Hu; Data extraction: Buyao Zhang and Qinlan Hou; Data analysis: Mingxia Li and Li Huang; Model development and deployment: Mingxia Li and Qinghe Zhuang; Manuscript preparation: Mingxia Li and Shuangping Zhao. All authors reviewed and approved the final manuscript.

Disclosure statement

The authors declare that they have no competing interests.

Funding

This study was supported by Natural Science Foundation of Hunan Province of China (grant numbers: 2020JJ4929 and S2020JJQNJJ1081), Research Project of Hunan Provincial Health Commission (grant number: 202217015418).

ORCID

Mingxia Li (b) http://orcid.org/0000-0001-6567-6632

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- Al-Jaghbeer M, Dealmeida D, Bilderback A, et al. Clinical decision support for in-Hospital AKI. J Am Soc Nephrol. 2018;29(2):654–660.
- [2] Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015; 41(8):1411–1423.
- [3] Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet 2019;394(10212):1949–1964.
- [4] Yokota LG, Sampaio BM, Rocha EP, et al. Acute kidney injury in elderly patients: narrative review on incidence, risk factors, and mortality. Int J Nephrol Renovasc Dis. 2018;11:217–224.
- [5] Mataloun SE, Machado FR, Senna AP, et al. Incidence, risk factors and prognostic factors of acute renal failure in patients admitted to an intensive care unit. Braz J Med Biol Res. 2006;39(10):1339–1347.
- [6] Chawla LS, Bellomo R, Bihorac A, Acute Disease Quality Initiative Workgroup 16, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257.
- [7] Lameire NH, Levin A, Kellum JA, Conference Participants, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2021;100(3): 516–526.
- [8] Yan P, Duan X-J, Liu Y, et al. Acute kidney disease in hospitalized acute kidney injury patients. PeerJ. 2021; 9:e11400.
- [9] Andonovic M, Traynor JP, Shaw M, et al. Short-and long-term outcomes of intensive care patients with acute kidney disease. EClinicalMedicine. 2022;44: 101291.
- [10] Hsu RK, Siew ED. The growth of AKI: half empty or half full, it's the size of the glass that matters. Kidney Int. 2017;92(3):550–553.
- [11] He J, Lin J, Duan M. Application of machine learning to predict acute kidney disease in patients with sepsis associated acute kidney injury. Front Med (Lausanne). 2021;8:792974.

- [12] Hu X-Y, Liu D-W, Qiao Y-J, et al. Development and validation of a nomogram model to predict acute kidney disease after nephrectomy in patients with renal cell carcinoma. Cancer Manag Res. 2020;12:11783–11791.
- [13] Mizuguchi KA, Huang C-C, Shempp I, et al. Predicting kidney disease progression in patients with acute kidney injury after cardiac surgery. J Thorac Cardiovasc Surg. 2018;155(6):2455–2463.
- [14] Chen Y-T, Jenq C-C, Hsu C-K, et al. Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients. BMC Nephrol. 2020;21(1):1–11.
- [15] Xiao Y-Q, Cheng W, Wu X, et al. Novel risk models to predict acute kidney disease and its outcomes in a Chinese hospitalized population with acute kidney injury. Sci Rep. 2020;10(1):1–11.
- [16] Yan P, Duan SB, Luo XQ, et al. Development and validation of a deep neural network-based model to predict acute kidney injury following intravenous administration of iodinated contrast media in hospitalized patients with chronic kidney disease: a multicohort analysis. Nephrol Dial Transplant. 2022;gfac049.
- [17] Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV" (version 1.0). PhysioNet. 2021. Available from:
- [18] Pollard TJ, Johnson AEW, Raffa JD, et al. The elCU collaborative research database, a freely available multicenter database for critical care research. Sci Data. 2018;5:180178.
- [19] World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull WHO. 2001;79(4):373.
- [20] Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:q7594.
- [21] Group K. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;2(1):138
- [22] Infante B, Franzin R, Madio D, et al. Molecular mechanisms of AKI in the elderly: from animal models to therapeutic intervention. JCM. 2020;9(8):2574.
- [23] Li S, Miller-Wilso L-A, Guo H, et al. Establishment and external validation of an online dynamic nomogram for predicting in-hospital death risk in sepsis-associated acute kidney disease. Curr Med Res Opin. 2022; 1–16.
- [24] Peng J-C, Wu T, Wu X, et al. Development of mortality prediction model in the elderly hospitalized AKI patients. Sci Rep. 2021;11(1):1–10.
- [25] Gameiro J, Carreiro C, Fonseca JA, et al. Acute kidney disease and long-term outcomes in critically ill acute kidney injury patients with sepsis: a cohort analysis. Clin Kidney J. 2021;14(5):1379–1387.
- [26] Zhang G, Xu J, Yu M, et al. A machine learning approach for mortality prediction only using non-invasive parameters. Med Biol Eng Comput. 2020;58(10): 2195–2238.
- [27] Karakike E, Kyriazopoulou E, Tsangaris I, et al. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. Crit Care. 2019;23(1):1–8.
- [28] Gao G, Wu X, Feng J, et al. Clinical characteristics and outcomes in patients with traumatic brain injury in

China: a prospective, multicentre, longitudinal, observational study. Lancet Neurol. 2020;19(8):670–677.

- [29] Abdallah A, Demaerschalk BM, Kimweri D, et al. A comparison of the full outline of unresponsiveness (FOUR) and glasgow coma scale (GCS) scores in predicting mortality among patients with reduced level of consciousness in Uganda. Neurocrit Care. 2020; 32(3):734–741.
- [30] Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North america and Australia between 2009 and 2019—results from a systematic review and meta-analysis. Crit Care. 2020; 24(1):1–9.
- [31] Basile-Filho A, Lago A, Menegueti M, et al. The use of APACHE II, SOFA, SAPS 3, C-reactive protein/albumin ratio, and lactate to predict mortality of surgical critically ill patients: a retrospective cohort study. Medicine (Baltimore). 2019;98(26):e16204.
- [32] Elias A, Agbarieh R, Saliba W, et al. SOFA score and short-term mortality in acute decompensated heart failure. Sci Rep. 2020;10(1):1–10.
- [33] Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247.

- [34] Maheshwari K, Nathanson BH, Munson SH, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018;44(6):857–867.
- [35] Poukkanen M, Wilkman E, Vaara ST, the FINNAKI Study Group, et al. Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. Crit Care. 2013;17(6):R295–11.
- [36] Bagshaw SM, Lapinsky S, Dial S, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009;35(5):871–881.
- [37] Peerapornratana S, Priyanka P, Wang S, ProCESS and ProGReSS-AKI Investigators, et al. Sepsis-associated acute kidney disease. Kidney Int Rep. 2020;5(6):839–850.
- [38] Selby NM, Casula A, Lamming L, et al. An organizational-level program of intervention for AKI: a pragmatic stepped wedge cluster randomized trial. J Am Soc Nephrol. 2019;30(3):505–515.
- [39] Prendecki M, Blacker E, Sadeghi-Alavijeh O, et al. Improving outcomes in patients with acute kidney injury: the impact of hospital based automated AKI alerts. Postgrad Med J. 2016;92(1083):9–13.